Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
Sign Up to like & getrecommendations! Published in 2022 at "JCI Insight"
DOI: 10.1172/jci.insight.151353
Abstract: Systemic therapies for pancreatic ductal adenocarcinoma (PDAC) remain unsatisfactory. Clinical prognosis is particularly poor for tumor subtypes with activating aberrations in the MYC pathway, creating an urgent need for novel therapeutic targets. To unbiasedly find… read more here.
Keywords: pancreatic cancer; drug; prmt5 inhibitor; inhibitor sensitive ... See more keywords